The Effects of NAMPT Haplotypes and Metabolic Risk Factors on Circulating Visfatin/NAMPT Levels in Childhood Obesity

Overview

Journal Int J Obes (Lond)

Specialty Endocrinology

Date 2013 Oct 9

PMID 24100423

Citations 8

Authors

V A Belo

M R Luizon

R Lacchini

J A Miranda

C M M Lanna

D C Souza-Costa

J E Tanus-Santos

Affiliations

Soon will be listed here.

Abstract

Objective: Polymorphisms in the NAMPT gene, which encodes the adipocytokine visfatin/nicotinamide phosphorybosil transferase (NAMPT), affect the circulating visfatin/NAMPT levels and are associated with obesity and cardiovascular diseases. However, no study has tested the hypothesis that NAMPT haplotypes could affect visfatin/NAMPT levels in case of childhood obesity. We investigated the effects of traditional metabolic risk factors (MRFs) and NAMPT polymorphisms T/C (rs1319501) and A/G (rs3801266) or haplotypes on visfatin/NAMPT levels in obese children and adolescents, and whether NAMPT polymorphisms and/or haplotypes are associated with susceptibility to childhood obesity.

Methods: We studied 175 control, 99 obese and 82 obese with ⩾ 3 MRFs children and adolescents. Genotypes were determined by a Taqman allele discrimination assay and real-time PCR. The plasma visfatin/NAMPT level was measured using an enzyme immunoassay.

Results: Obese children and adolescents with ⩾ 3 MRFs had higher plasma visfatin/NAMPT levels in comparison with control children and adolescents (P<0.05). Although positive associations were observed between visfatin/NAMPT and body mass index (rs = 0.157; P = 0.034) as well as visfatin/NAMPT and waist circumference (rs = 0.192; P = 0.011), visfatin/NAMPT and high-density lipoprotein cholesterol were inversely associated (rs = -0.162; P = 0.031). No significant differences in genotype, allele or haplotype frequency distributions for the studied polymorphisms were found when the three groups were compared. However, higher plasma visfatin/NAMPT levels were found in control and obese subjects carrying the GG genotype for the A/G (rs3801266) polymorphism (P<0.05) but not in obese children with ⩾ 3 MRFs. Moreover, control subjects carrying the 'T-G' haplotype showed higher plasma visfatin/NAMPT levels. NAMPT genotypes or haplotypes were not associated with childhood obesity.

Conclusions: Obesity in children with ⩾ 3 MRFs increases plasma visfatin/NAMPT levels, and this marker was associated with body mass index and waist circumference. The A/G polymorphism and NAMPT haplotypes affect plasma visfatin/NAMPT levels in controls but not in obese children with ⩾ 3 MRFs. These results suggest that obesity and MRFs are more influential than genetic polymorphisms in the determination of visfatin/NAMPT levels in obese children. Further research is necessary to explain why the GG genotype is not associated with increased visfatin/NAMPT levels in obese children with ⩾ 3 MRFs.

Citing Articles

Assessing 48 SNPs in Hypertensive Paediatric Patients and Young Adults with Review of Genetic Background of Essential Hypertension.

Mocnik M, Zagradisnik B, Marcun Varda N Children (Basel). 2022; 9(8).

PMID: 36010152 PMC: 9406300. DOI: 10.3390/children9081262.

Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.

Dakroub A, Nasser S, Younis N, Bhagani H, Al-Dhaheri Y, Pintus G Cells. 2020; 9(11).

PMID: 33182523 PMC: 7696687. DOI: 10.3390/cells9112444.

Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population.

Javanmard S, Dehghananzadeh R, Rafiee L, Naji H, Rezayat A, Sarrafzadegan N J Res Med Sci. 2017; 21:105.

PMID: 28250782 PMC: 5322690. DOI: 10.4103/1735-1995.193177.

Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Luizon M, Palei A, Belo V, Amaral L, Lacchini R, Duarte G Pharmacogenomics J. 2016; 17(5):427-434.

PMID: 27168100 DOI: 10.1038/tpj.2016.35.

Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.

Larrad M, Anchuelo A, Fernandez Perez C, Perez Barba M, Lazcano Redondo Y, Serrano Rios M PLoS One. 2016; 11(5):e0153976.

PMID: 27166797 PMC: 4864316. DOI: 10.1371/journal.pone.0153976.

References

Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R . Serum visfatin increases with progressive beta-cell deterioration. Diabetes. 2006; 55(10):2871-5. DOI: 10.2337/db06-0259. View

Liu S, Qiao S, Yuan J, Liu D . Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf). 2009; 71(2):202-7. DOI: 10.1111/j.1365-2265.2008.03453.x. View

Dahl T, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A . Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115(8):972-80. DOI: 10.1161/CIRCULATIONAHA.106.665893. View

Van Gaal L, Mertens I, De Block C . Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444(7121):875-80. DOI: 10.1038/nature05487. View

Haider D, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O . The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr. 2006; 43(4):548-9. DOI: 10.1097/01.mpg.0000235749.50820.b3. View

Stephens M, Smith N, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet. 2001; 68(4):978-89. PMC: 1275651. DOI: 10.1086/319501. View

Belo V, Souza-Costa D, Luizon M, Izidoro-Toledo T, Lanna C, Pinheiro L . Vascular endothelial growth factor haplotypes associated with childhood obesity. DNA Cell Biol. 2011; 30(9):709-14. DOI: 10.1089/dna.2011.1260. View

Curat C, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R . Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006; 49(4):744-7. DOI: 10.1007/s00125-006-0173-z. View

Krzystek-Korpacka M, Patryn E, Bednarz-Misa I, Hotowy K, Noczynska A . Visfatin in juvenile obesity - the effect of obesity intervention and sex. Eur J Clin Invest. 2011; 41(12):1284-91. DOI: 10.1111/j.1365-2362.2011.02538.x. View

10.

Bailey S, Loredo-Osti J, Lepage P, Faith J, Fontaine J, Desbiens K . Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes. 2006; 55(10):2896-902. DOI: 10.2337/db06-0189. View

11.

Wang L, Yan J, Tang N, Zhu J, Wang Y, Wang Q . A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep. 2010; 38(2):819-25. DOI: 10.1007/s11033-010-0171-6. View

12.

Chang Y, Chang D, Lin K, Shin S, Lee Y . Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011; 27(6):515-27. DOI: 10.1002/dmrr.1201. View

13.

Belo V, Luizon M, Carneiro P, Gomes V, Lacchini R, Lanna C . Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep. 2012; 40(3):2697-704. DOI: 10.1007/s11033-012-2356-7. View

14.

Adya R, Tan B, Punn A, Chen J, Randeva H . Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2007; 78(2):356-65. DOI: 10.1093/cvr/cvm111. View

15.

Leander K, Gigante B, Silveira A, Vikstrom M, Hamsten A, Hogberg J . NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction. Clin Chim Acta. 2012; 413(7-8):727-32. DOI: 10.1016/j.cca.2012.01.002. View

16.

Keskin M, Kurtoglu S, Kendirci M, Atabek M, Yazici C . Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005; 115(4):e500-3. DOI: 10.1542/peds.2004-1921. View

17.

Crawford D, Nickerson D . Definition and clinical importance of haplotypes. Annu Rev Med. 2005; 56:303-20. DOI: 10.1146/annurev.med.56.082103.104540. View

18.

Tabassum R, Mahendran Y, Dwivedi O, Chauhan G, Ghosh S, Marwaha R . Common variants of IL6, LEPR, and PBEF1 are associated with obesity in Indian children. Diabetes. 2012; 61(3):626-31. PMC: 3282821. DOI: 10.2337/db11-1501. View

19.

Davutoglu M, Ozkaya M, Guler E, Garipardic M, Gursoy H, Karabiber H . Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices. Swiss Med Wkly. 2009; 139(1-2):22-7. DOI: 10.4414/smw.2009.12400. View

20.

Haider D, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B . Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006; 91(4):1578-81. DOI: 10.1210/jc.2005-2248. View